TOP TEN perturbations for 1553347_s_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553347_s_at
Selected probe(set): 1553347_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553347_s_at (1553347_s_at) across 6672 perturbations tested by GENEVESTIGATOR:

null cell adenoma study 1 / normal pituitary gland tissue

Relative Expression (log2-ratio):1.5483856
Number of Samples:2 / 8
Experimental null cell adenoma study 1
Null cell adenoma biopsy samples recovered during transsphenoidal surgery. The tumors were defined by gonadotropic staining for FSH, LH, or alpha subunit in less than 5-10% of cells. Samples were scanned between 04/6/2004 - 15/4/2005.
Control normal pituitary gland tissue
Biopsy samples of healthy pituitary gland recovered post-mortem during autopsy within 2-18 hours of death. Cause of death were mostly various pulmonary or cardiovascular conditions.

brain tumor study 1 (medulloblastoma) / brain tumor study 1 (ependymoma)

Relative Expression (log2-ratio):-1.4770727
Number of Samples:22 / 46
Experimental brain tumor study 1 (medulloblastoma)
Primary tumor tissue sample from the brain of patients with medulloblastoma.
Control brain tumor study 1 (ependymoma)
Primary tumor tissue sample from the brain of patients with ependymoma.

brain tumor study 1 (glioblastoma) / brain tumor study 1 (ependymoma)

Relative Expression (log2-ratio):-1.3775072
Number of Samples:34 / 46
Experimental brain tumor study 1 (glioblastoma)
Primary tumor tissue sample from the brain of patients with glioblastoma multiformae.
Control brain tumor study 1 (ependymoma)
Primary tumor tissue sample from the brain of patients with ependymoma.

brain tumor study 1 (ependymoma) / normal brain tissue

Relative Expression (log2-ratio):1.2635155
Number of Samples:46 / 12
Experimental brain tumor study 1 (ependymoma)
Primary tumor tissue sample from the brain of patients with ependymoma.
Control normal brain tissue
Histologically normal and non-neoplastic tissue sample from different brain anatomical sites of patients with primary brain tumors.

gonadotroph adenoma study 1 / normal pituitary gland tissue

Relative Expression (log2-ratio):1.1889992
Number of Samples:7 / 8
Experimental gonadotroph adenoma study 1
Gonadotroph adenoma biopsy samples recovered during transsphenoidal surgery. The tumors were defined as demonstrating positive immunostaining for FSH, LH, or alpha subunit in greater than 5-10% of cells. Samples were scanned between 04/6/2004 - 15/4/2005.
Control normal pituitary gland tissue
Biopsy samples of healthy pituitary gland recovered post-mortem during autopsy within 2-18 hours of death. Cause of death were mostly various pulmonary or cardiovascular conditions.

brain tumor study 1 (pilocytic astrocytoma) / brain tumor study 1 (ependymoma)

Relative Expression (log2-ratio):-1.0533895
Number of Samples:15 / 46
Experimental brain tumor study 1 (pilocytic astrocytoma)
Primary tumor tissue sample from the brain of patients with pilocytic astrocytoma.
Control brain tumor study 1 (ependymoma)
Primary tumor tissue sample from the brain of patients with ependymoma.

psoriasis study 24 (lesional; etanercept; 12wk; 50mg; non-responder) / psoriasis study 24 (lesional; baseline; ustekinumab; 45mg; non-responder)

Relative Expression (log2-ratio):0.99676514
Number of Samples:10 / 2
Experimental psoriasis study 24 (lesional; etanercept; 12wk; 50mg; non-responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at 12 week after treatment with 50 mg etanercept and assigned as non-responders. Etanercept was administered subcutaneously in dose of 50 mg twice weekly. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT. ATC code:
Control psoriasis study 24 (lesional; baseline; ustekinumab; 45mg; non-responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with 45 mg ustekinumab) and assigned as non-responders. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT.

brain aging study 5 (advanced age) / brain aging study 5 (young adult)

Relative Expression (log2-ratio):-0.9097996
Number of Samples:14 / 12
Experimental brain aging study 5 (advanced age)
Postmortem superior frontal gyrus tissue from neuropathologically and cognitively normal advanced aged individuals (80-99 years old).
Control brain aging study 5 (young adult)
Postmortem superior frontal gyrus tissue from neuropathologically and cognitively normal young adult individuals (20-39 years old).

glioma study 17 (glioblastoma; unsorted) / non-tumor cortical tissue

Relative Expression (log2-ratio):-0.8406086
Number of Samples:2 / 4
Experimental glioma study 17 (glioblastoma; unsorted)
Brain cells isolated from high grade glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation.
Control non-tumor cortical tissue
Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses.

brain aging study 5 (old age) / brain aging study 5 (young adult)

Relative Expression (log2-ratio):-0.8310871
Number of Samples:12 / 12
Experimental brain aging study 5 (old age)
Postmortem superior frontal gyrus tissue from neuropathologically and cognitively normal old individuals (60-79 years old).
Control brain aging study 5 (young adult)
Postmortem superior frontal gyrus tissue from neuropathologically and cognitively normal young adult individuals (20-39 years old).

Organism: Homo sapiens
Gene: 1553347_s_at
Selected probe(set): 205616_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553347_s_at (205616_at) across 6672 perturbations tested by GENEVESTIGATOR:

CNS cancer study 1 (PDX; glioma, malignant, NOS; primary) / CNS cancer study 1 (PDX; ependymoma, NOS; primary)

Relative Expression (log2-ratio):2.3512802
Number of Samples:2 / 2
Experimental CNS cancer study 1 (PDX; glioma, malignant, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary glioma, malignant, NOS of the central nervous system (subcutaneously implanted).
Control CNS cancer study 1 (PDX; ependymoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary ependymoma, NOS of the central nervous system (subcutaneously implanted).

CNS cancer study 1 (PDX; glioma, malignant, NOS; primary) / CNS cancer study 1 (PDX; glioblastoma, NOS; primary)

Relative Expression (log2-ratio):2.2227392
Number of Samples:2 / 3
Experimental CNS cancer study 1 (PDX; glioma, malignant, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary glioma, malignant, NOS of the central nervous system (subcutaneously implanted).
Control CNS cancer study 1 (PDX; glioblastoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary glioblastoma, NOS of the central nervous system (subcutaneously implanted).

atypical teratoid/rhabdoid tumor study 1 / non-tumor brain tissue

Relative Expression (log2-ratio):-2.044855
Number of Samples:20 / 9
Experimental atypical teratoid/rhabdoid tumor study 1
Primary tumor tissue sample from the brain of pediatric patients with atypical teratoid/rhabdoid tumor (AT/RT).
Control non-tumor brain tissue
Histologically normal brain tissue at rapid autopsy from patients who died from atypical teratoid/rhabdoid tumor.

diphenylcyclopropenone study 1 (late) / diphenylcyclopropenone study 1 (early)

Relative Expression (log2-ratio):1.7900457
Number of Samples:6 / 10
Experimental diphenylcyclopropenone study 1 (late)
Skin biopsy samples of healthy volunteers exposed to diphenylcyclopropenone (diphencyprone; DPCP) for 4 to 8 months. ATC code:---
Control diphenylcyclopropenone study 1 (early)
Skin biopsy samples of healthy volunteers exposed to diphenylcyclopropenone (diphencyprone; DPCP) for 3 days. ATC code:---

diphenylcyclopropenone study 1 (late) / diphenylcyclopropenone study 1 (intermediate)

Relative Expression (log2-ratio):1.7120094
Number of Samples:6 / 10
Experimental diphenylcyclopropenone study 1 (late)
Skin biopsy samples of healthy volunteers exposed to diphenylcyclopropenone (diphencyprone; DPCP) for 4 to 8 months. ATC code:---
Control diphenylcyclopropenone study 1 (intermediate)
Skin biopsy samples of healthy volunteers exposed to diphenylcyclopropenone (diphencyprone; DPCP) for 14 days. ATC code:---

medulloblastoma study 2 / non-tumor brain tissue

Relative Expression (log2-ratio):-1.6973324
Number of Samples:4 / 9
Experimental medulloblastoma study 2
Primary tumor tissue sample from the infratentorial brain of pediatric patients with large-cell anaplastic medulloblastoma.
Control non-tumor brain tissue
Histologically normal brain tissue at rapid autopsy from patients who died from atypical teratoid/rhabdoid tumor.

influenza virus study 11 (A/H5N3) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-1.6964989
Number of Samples:3 / 3
Experimental influenza virus study 11 (A/H5N3)
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

stem cell differentiation study 59 (iDRG; 12d) / stem cell differentiation study 59 (8d)

Relative Expression (log2-ratio):1.690381
Number of Samples:4 / 4
Experimental stem cell differentiation study 59 (iDRG; 12d)
Immature dorsal root ganglia neurons (iDRGs) obtained by differentiation of WA09 embryonic stem cells. WA09 cells were differentiated for 8 days and subsequently cryopreserved. After thawing, cells were further differentiated for 4 days. Further details are described in the paper.
Control stem cell differentiation study 59 (8d)
WA09 embryonic stem cell samples differentiated for 8 days. Further details are described in the paper.

stem cell differentiation study 59 (iDRG; 12d) / normal embryonic stem cell sample (WA09)

Relative Expression (log2-ratio):1.6779099
Number of Samples:4 / 4
Experimental stem cell differentiation study 59 (iDRG; 12d)
Immature dorsal root ganglia neurons (iDRGs) obtained by differentiation of WA09 embryonic stem cells. WA09 cells were differentiated for 8 days and subsequently cryopreserved. After thawing, cells were further differentiated for 4 days. Further details are described in the paper.
Control normal embryonic stem cell sample (WA09)
Undifferentiated WA09 embryonic stem cell samples.

diphenylcyclopropenone study 1 (early) / placebo treated skin tissue

Relative Expression (log2-ratio):-1.6486816
Number of Samples:10 / 11
Experimental diphenylcyclopropenone study 1 (early)
Skin biopsy samples of healthy volunteers exposed to diphenylcyclopropenone (diphencyprone; DPCP) for 3 days. ATC code:---
Control placebo treated skin tissue
Skin biopsy samples of healthy volunteers exposed to placebo for 3 days.